Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ijms21103547
Keywords
diabetic retinopathy; ROR gamma t; SR1001; retinal inflammation; capillary degeneration
Funding
- Research to Prevent Blindness Foundation
- Ohio Lions Eye Research Foundation
- [VA BX003403]
- [RO1 EY030487]
- [P30 EY011373]
Ask authors/readers for more resources
Diabetic retinopathy is a diabetes-mediated retinal microvascular disease that is the leading cause of blindness in the working-age population worldwide. Interleukin (IL)-17A is an inflammatory cytokine that has been previously shown to play a pivotal role in the promotion and progression of diabetic retinopathy. Retinoic acid-related orphan receptor gammaT (ROR gamma t) is a ligand-dependent transcription factor that mediates IL-17A production. However, the role of ROR gamma t in diabetes-mediated retinal inflammation and capillary degeneration, as well as its potential therapeutic attributes for diabetic retinopathy has not yet been determined. In the current study, we examined retinal inflammation and vascular pathology in streptozotocin-induced diabetic mice. We found ROR gamma t expressing cells in the retinal vasculature of diabetic mice. Further, diabetes-mediated retinal inflammation, oxidative stress, and retinal endothelial cell death were all significantly lower in ROR gamma t(-/-) mice. Finally, when a ROR gamma t small molecule inhibitor (SR1001) was subcutaneously injected into diabetic mice, retinal inflammation and capillary degeneration were ameliorated. These findings establish a pathologic role for ROR gamma t in the onset of diabetic retinopathy and identify a potentially novel therapeutic for this blinding disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available